Keyphrases
Acute Myeloid Leukemia
44%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
84%
Allogeneic Transplantation
11%
Autologous Transplantation
14%
Bortezomib
15%
Carfilzomib
13%
Carmustine
13%
CD34+
11%
CD34+ Cells
12%
Chemotherapy
19%
Complete Remission
20%
Confidence Interval
14%
COVID-19
13%
Cyclophosphamide
15%
Cytarabine
10%
Engraftment
11%
Etoposide
15%
Event-free Survival
13%
Graft-versus-host Disease (GvHD)
30%
Granulocyte Colony-stimulating Factor (G-CSF)
36%
Hematological Malignancies
16%
Hematopoietic Cell Transplantation
26%
Hematopoietic Stem Cells
11%
High Dose
18%
High Risk
13%
High-dose Chemotherapy
16%
High-dose Therapy
16%
Lenalidomide
21%
Leukemia
14%
Leukemia Patients
10%
Melphalan
11%
Metastatic Breast Cancer
11%
Multiple Myeloma
100%
Myelodysplastic Syndrome
20%
Myeloma
14%
NCCN Guidelines
16%
Non-Hodgkin Lymphoma
18%
Overall Response Rate
12%
Overall Survival
26%
Peripheral Blood
10%
Peripheral Blood Progenitor Cells
14%
Phase I Study
10%
Phase II Study
18%
Phase II Trial
12%
Plerixafor
18%
Pomalidomide
13%
Relapsed or Refractory
11%
Relapsed or Refractory Acute Myeloid Leukemia
10%
Relapsed or Refractory multiple Myeloma
22%
Transplantation
16%
Medicine and Dentistry
Acute Myeloid Leukemia
34%
Allogeneic Stem Cell Transplantation
7%
Allograft
6%
Amyloidosis
9%
Azacitidine
7%
Bortezomib
12%
Breast Cancer
8%
Carfilzomib
12%
Carmustine
10%
Cell Transplantation
49%
Clinical Research
6%
Comorbidity
6%
COVID-19
20%
Cyclophosphamide
8%
Decitabine
7%
Dexamethasone
18%
Diseases
22%
Drug Megadose
27%
Elotuzumab
7%
Etoposide
8%
Event Free Survival
8%
Graft Versus Host Reaction
11%
Granulocyte Colony Stimulating Factor
15%
Hematologic Malignancy
9%
Hematopoietic Cell
61%
High Dose Chemotherapy
11%
Immunoglobulin Idiotype
6%
Infection
8%
Lenalidomide
16%
Leukemia
10%
Light Chain
7%
Malignant Neoplasm
19%
Metastatic Breast Cancer
8%
Multiple Myeloma
91%
Myelodysplastic Syndrome
9%
Myeloma
15%
Natural Killer Cell
7%
Neoplasm
6%
Non-Hodgkin Lymphoma
11%
Oncology
18%
Overall Survival
22%
Plerixafor
10%
Pomalidomide
7%
Progression Free Survival
9%
Stem Cell
8%
Stem Cell Mobilization
6%
Stem Cell Therapy
7%
Stem Cell Transplant
12%
Transplantation
16%
Whole Body Radiation
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
5%
Acute Myeloid Leukemia
26%
Adverse Event
7%
Amyloidosis
7%
Azacitidine
10%
Bendamustine
7%
Bortezomib
15%
Breast Cancer
5%
Carfilzomib
10%
Carmustine
16%
Chemotherapy
30%
Chronic Graft Versus Host Disease
6%
Clinical Research
6%
Clofarabine
5%
Cyclophosphamide
15%
Cytarabine
10%
Decitabine
7%
Dexamethasone
20%
Diseases
26%
Elotuzumab
7%
Etoposide
13%
Event Free Survival
8%
Graft Versus Host Reaction
16%
Granulocyte Colony Stimulating Factor
16%
Hematologic Malignancy
9%
High Dose Chemotherapy
9%
Infection
7%
Lenalidomide
19%
Malignant Neoplasm
13%
Melphalan
13%
Metastatic Breast Cancer
8%
Multiple Myeloma
73%
Myelodysplastic Syndrome
16%
Myeloma
8%
Neoplasm
6%
Nonhodgkin Lymphoma
13%
Overall Survival
23%
Plasma Cell Leukemia
5%
Plerixafor
12%
Pomalidomide
7%
Prednisone
8%
Progression Free Survival
10%
Remission
20%
Thiotepa
5%